SNORD79: A Potential Drug Target and Biomarker (G26770)

Target Name: SNORD79

NCBI ID: G26770

SNORD79

Other Name(s): small nucleolar RNA, C/D box 79 | RNU103 | Small nucleolar RNA, C/D box 79 | Z22 | U79

SNORD79: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD79, which is located in the C/D box 79 of the 28S rRNA molecule.

SNORD79 is a small RNA molecule that contains 79 amino acid residues and is primarily localized to the cytoplasm of eukaryotic cells. It is expressed in a variety of tissues and cells, including muscle, heart, liver, and brain, and is involved in the regulation of gene expression and cellular processes such as cell growth, apoptosis, and transcriptional regulation.

SNORD79 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the key reasons for its potential as a drug target is its expression in a variety of tissues, which makes it an attractive target for therapeutic intervention. Additionally, its role in regulating gene expression has been confirmed by various experiments, including RNA sequencing and gene knockout experiments.

SNORD79 has also been shown to be involved in the regulation of cellular processes that are important for human health, such as cell apoptosis and cancer progression. In particular, studies have shown that SNORD79 is involved in the regulation of apoptosis, which is a natural and necessary process for the elimination of damaged or dysfunctional cells.

SNORD79 has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. TGF-β is a well-known signaling pathway that is involved in the regulation of cell growth, differentiation, and survival, and is a potential target for many therapeutic drugs.

SNORD79 has also been identified as a potential biomarker for a variety of diseases, including cancer. Its expression has been shown to be increased in a variety of cancer types, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that SNORD79 can be used as a diagnostic biomarker for cancer, using techniques such as qRT-PCR and western blotting.

In conclusion, SNORD79 is a small RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and its involvement in various cellular processes make it an attractive target for therapeutic intervention. Further research is needed to fully understand the role of SNORD79 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 79

The "SNORD79 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD79 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets